Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Directors
Effective September 7, 2018, David L. White, and effective September 11, 2018, Uwe Sommer, each resigned as a Director of Osiris Therapeutics, Inc. (the “Company”). Neither
Mr. White’s nor Mr. Sommer’s resignation was caused by any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Sommer resigned to pursue a business opportunity in the consumer goods industry that does not permit him to continue his Board activities with the Company.
Appointment of Director
On September 11, 2018, the Board of Directors of the Company (the” Board”), upon recommendation of its Nominating Committee, appointed Mr. Charles A. Reinhart, C.P.A, M.B.A., as a Director. Mr. Reinhart will serve as the Chairperson for the Company’s Audit Committee.
Mr. Reinhart is currently the Chief Financial Officer of Pacira Pharmaceuticals, Inc. Prior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc., Archimedes Pharma Ltd. and PharmAthene, Inc. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. Mr. Reinhart has 30 plus years of experience building and managing finance and accounting organizations, raising capital, managing risks and implementing corporate development initiatives.
Mr. Reinhart will be entitled to receive the compensation received by Board members under the Company’s standard compensation policy and practices, which are described under the caption “Corporate Governance and Board Matters - Compensation of Directors” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 11, 2018, as may be adjusted by the Board from time to time. Mr. Reinhart does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.